MedTrace Logo

Terbinafine Treatment of Axial Spondyloarthropathy

NCT05119712 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2023-08-28

No results posted yet for this study

Summary

This is a pilot study to determine if further research is warranted to assess if anti-fungal therapy is an effective adjunctive treatment for axial spondyloarthropathy

Conditions

  • Ankylosing Spondylitis
  • Axial Spondyloarthritis
  • Psoriatic Spondylitis
  • Spondylitis Secondary to Inflammatory Bowel Disease
  • Axial Spondyloarthopathy

Interventions

DRUG

Terbinafine Tablets

500mg oral terbinafine or placebo daily

DIAGNOSTIC_TEST

Laboratory Testing

Laboratory testing at screening, baseline, week 8, 16, 24 and 32.

DIAGNOSTIC_TEST

Laboratory Testing

Subjects with the potential to become pregnant will have a baseline urine pregnancy test prior to starting study drug.

Sponsors & Collaborators

  • The Malassezia Foundation

    collaborator UNKNOWN

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Atul Deodhar, M.D. · Oregon Health and Science University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-09
Primary Completion
2023-10-15
Completion
2024-10-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05119712 on ClinicalTrials.gov